Survival of the fittest: Cancer stem cells in therapeutic resistance and angiogenesis

Journal of Clinical Oncology

Volumn 26, Issue 17, 2008, Pages 2839-2845

  Eyler, Christine E ^a   Rich, Jeremy N ^a  

^a DUKE UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANGIOGENESIS INHIBITOR; BETA CATENIN; BEVACIZUMAB; BREAST CANCER RESISTANCE PROTEIN; CARBOPLATIN; CETUXIMAB; CYCLOPHOSPHAMIDE; DAUNORUBICIN; ERLOTINIB; ETOPOSIDE; FLUOROURACIL; GEMCITABINE; IMATINIB; METHOTREXATE; MITOXANTRONE; MULTIDRUG RESISTANCE PROTEIN 1; NOTCH RECEPTOR; OXALIPLATIN; PACLITAXEL; TEMOZOLOMIDE; TOPOTECAN; VANDETANIB; VINBLASTINE; ANTINEOPLASTIC AGENT;

ADVANCED CANCER; ANGIOGENESIS; ANTIANGIOGENIC ACTIVITY; ANTIANGIOGENIC THERAPY; ANTINEOPLASTIC ACTIVITY; BREAST CANCER; CANCER CHEMOTHERAPY; CANCER RADIOTHERAPY; CANCER RECURRENCE; CANCER RESISTANCE; CANCER STEM CELL; CELL DEATH; CELL POPULATION; CELL RENEWAL; CELL SURVIVAL; COLON CANCER; DNA DAMAGE; DNA REPAIR; DNA REPLICATION; DRUG MECHANISM; GENOMIC INSTABILITY; GLIOBLASTOMA; GLIOMA; HUMAN; INNATE IMMUNITY; LEUKEMIA CELL; LIVER CELL CARCINOMA; NONHUMAN; PRIORITY JOURNAL; RADIOSENSITIVITY; REVIEW; SOLID TUMOR; ANIMAL; CELL DIFFERENTIATION; CELL PROLIFERATION; DRUG EFFECT; DRUG RESISTANCE; NEOPLASM; NEOVASCULARIZATION (PATHOLOGY); PATHOLOGY; RADIATION EXPOSURE; RADIOTHERAPY; TREATMENT FAILURE; VASCULARIZATION;

ANGIOGENESIS INHIBITORS; ANIMALS; ANTINEOPLASTIC AGENTS; CELL DIFFERENTIATION; CELL PROLIFERATION; CELL SURVIVAL; DRUG RESISTANCE, NEOPLASM; HUMANS; NEOPLASMS; NEOPLASTIC STEM CELLS; NEOVASCULARIZATION, PATHOLOGIC; RADIOTHERAPY; TREATMENT FAILURE;

EID: 45549093647     PISSN: 0732183X     EISSN: None     Source Type: Journal    
DOI: 10.1200/JCO.2007.15.1829     Document Type: Review

References (74)

1. Reya T, Morrison SJ, Clarke MF, et al: Stem cells, cancer, and cancer stem cells. Nature 414: 105-111, 2001
2. Scheck AC, Shapiro JR, Coons SW, et al: Biological and molecular analysis of a low-grade recurrence of a glioblastoma multiforme. Clin Cancer Res 2:187-199, 1996
3. Abbott A: Cancer: The root of the problem. Nature 442:742-743, 2006
4. Wicha MS, Liu S, Dontu G: Cancer stem cells: An old idea - A paradigm shift. Cancer Res 66:1883-1890, 2006
5. Cohnheim J: Ueber entzundung und eiterung. Path Anat Physiol Klin Med 40:1-79, 1867
6. Cohnheim J: Congenitales, quergestreiftes Muskelsarkon der Nireren. Virchows Arch 65:64-69, 1875
7. Durante F: Nesso fisio-pathologico tra la struttura dei mei materni e la genesi di aleuni tumori maligni. Arch Memor Observ Chir Pract 11:217-226, 1874
8. Park CH, Bergsagel DE, McCulloch EA: Mouse myeloma tumor stem cells: A primary cell culture assay. J Natl Cancer Inst 46:411-422, 1971
9. Bruce WR, Gaag H: A quantitative assay for the number of murine lymphoma cells capable of proliferation in vivo. Nature 199:79-80, 1963
10. Bergsagel DE, Valeriote FA: Growth characteristics of a mouse plasma cell tumor. Cancer Res 28:2187-2196, 1968
11. Wodinsky I, Swiniarski J, Kensler CJ: Spleen colony studies of leukemia L1210: I. Growth kinetics of lymphocytic L1210 cells in vivo as determined by spleen colony assay Cancer Chemother Rep 51:415-421, 1967
12. Spangrude GJ, Heimfeld S, Weissman IL: Purification and characterization of mouse hematopoietic stem cells. Science 241:58-62, 1988
13. Bonnet D, Dick JE: Human acute myeloid leukemia is organized as a hierarchy that originates from a primitive hematopoietic cell. Nat Med 3:730-737, 1997
14. Jordan CT, Guzman ML, Noble M: Cancer stem cells. N Engl J Med 355:1253-1261, 2006
15. Clarke MF, Dick JE, Dirks PB, et al: Cancer stem cells: Perspectives on current status and future directions - AASCR workshop on cancer stem cells. Cancer Res 66:9339-9344, 2006
16. Singh SK, Clarke ID, Terasaki M, et al: Identification of a cancer stem cell in human brain tumors. Cancer Res 63:5821-5828, 2003
17. Singh SK, Hawkins C, Clarke ID, et al: Identification of human brain tumour initiating cells. Nature 432:396-401, 2004
18. Hemmati HD, Nakano I, Lazareff JA, et al: Cancerous stem cells can arise from pediatric brain tumors. Proc Natl Acad Sci U S A 100:15178-15183, 2003
19. Galli R, Binda E, Orfanelli U, et al: Isolation and characterization of tumorigenic, stem-like neural precursors from human glioblastoma. Cancer Res 64:7011-7021, 2004
20. Ignatova TN, Kukekov VG, Laywell ED, et al: Human cortical glial tumors contain neural stem-like cells expressing astroglial and neuronal markers in vitro. Glia 39:193-206, 2002
21. Al-Hajj M, Wicha MS, Benito-Hernandez A, et al: Prospective identification of tumorigenic breast cancer cells. Proc Natl Acad Sci U S A 100:3983-3988, 2003
22. O'Brien CA, Pollett A, Gallinger S, et al: A human colon cancer cell capable of initiating tumour growth in immunodeficient mice. Nature 445:106-110, 2007
23. Ricci-Vitiani L, Lombardi DG, Pilozzi E, et al: Identification and expansion of human colon-cancer-initiating cells. Nature 445:111-115, 2007
24. Li C, Heidt DG, Dalerba P, et al: Identification of pancreatic cancer stem cells. Cancer Res 67: 1030-1037, 2007
25. Patrawala L, Calhoun T, Schneider-Broussard R, et al: Highly purified CD44+ prostate cancer cells from xenograft human tumors are enriched in tumorigenic and metastatic progenitor cells. Oncogene 25:1696-1708, 2006
26. Fang D, Nguyen TK, Leishear K, et al: A tumorigenic subpopulation with stem cell properties in melanomas. Cancer Res 65:9328-9337, 2005
27. Ma S, Chan KW, Hu L, et al: Identification and characterization of tumorigenic liver cancer stem/progenitor cells. Gastroenterology 132:2542-2556, 2007
28. Prince ME, Sivanandan R, Kaczorowski A, et al: Identification of a subpopulation of cells with cancer stem cell properties in head and neck squamous cell carcinoma. Proc Natl Acad Sci U S A 104:973-978, 2007
29. Bao S, Wu Q, McLendon RE, et al: Glioma stem cells promote radioresistance by preferential activation of the DNA damage response. Nature 444:756-760, 2006
30. Gorgoulis VG, Vassiliou L-VF, Karakaidos P, et al: Activation of the DNA damage checkpoint and genomic instability in human precancerous lesions. Nature 434:907-913, 2005
31. Bartkova J, Horejsi Z, Koed K, et al: DNA damage response as a candidate anti-cancer barrier in early human tumorigenesis. Nature 434:864-870, 2005
32. Woodward WA, Chen MS, Behbod F, et al: Wnt/b-catenin mediates radiation resistance of mouse mammary progenitor cells. Proc Natl Acad Sci U S A 104:618-623, 2007
33. Chen MS, Woodward WA, Behbod F, et al: Wnt/b-catenin mediates radiation resistance of Sca1+ progenitors in an immortalized mammary gland cell line. J Cell Sci 120:468-477, 2007
34. Reya T, Clevers H: Wnt signaling in stem cells and cancer. Nature 434:843-850, 2005
35. Idogawa M, Masutani M, Shitashige M, et al: Ku70 and poly(ADP-ribose) polymerase-1 competitively regulate b-catenin and T-cell factor-4-mediated gene transactivation: Possible linkage of DNA damage recognition and Wnt signaling. Cancer Res 67:911-918, 2007
36. Hadjihannas MV, Bruckner M, Jerchow B, et al: Aberrant Wnt/b-catenin signaling can induce chromosomal instability in colon cancer. Proc Natl Acad Sci U S A 103:10747-10752, 2006
37. Shiras A, Chettiar S, Shepal V, et al: Spontaneous transformation of human adult nontumorigenic stem cells to cancer stem cells is driven by genomic instability in a human model of glioblastoma. Stem Cells 25:1478-1489, 2007
38. Phillips TM, McBride WH, Pajonk F: The response of CD24 -/low / CD44+ breast cancer-initiating cells to radiation. J Natl Cancer I 98:1777-1785, 2006
39. Clement V, Sanchez P, Tribolet ND, et al: HEDGEHOG-GLI1 signaling regulates human glioma growth, cancer stem cell self-renewal, and tumorigenicity. Curr Biol 17:165-172, 2007
40. Damiano V, Melisi D, Bianco C, et al: Cooperative anti-tumor effect of multitargeted kinase inhibitor ZD6474 and ionizing radiation in glioblastoma. Clin Cancer Res 11:5639-5644, 2005
41. Chakravarti A, Chakladar A, Delaney MA, et al: The epidermal growth factor receptor pathway mediates resistance to sequential administration of radiation and chemotherapy in primary human glioblastoma cells in a RAS-dependent manner. Cancer Res 62:4307-4315, 2002
42. Lammering G, Hewit TH, Holmes M, et al: Inhibition of the type III epidermal growth factor receptor variant mutant receptor by dominant-negative EGFR-CD533 enhances malignant glioma cell radiosensitivity. Clin Cancer Res 10:6732-6743, 2004
43. Puc J, Keniry M, Li HS, et al: Lack of PTEN sequesters CHK1 and initiates genetic instability. Cancer Cell 7:193-204, 2005
44. Hermann PC, Huber SL, Herrier T, et al: Distinct populations of cancer stem cells determine tumor growth and metastatic activity in human pancreatic cancer. Cell Stem Cell 1:313-323, 2007
45. Ma S, Lee TK, Zheng B-J, et al: CD133+ HCC cancer stem cells confer chemoresistance by preferential expression of the Akt/PKB survival pathway. Oncogene 27:1749-1758, 2008
46. Liu G, Yuan X, Zeng Z, et al: Analysis of gene expression and chemoresistance of CD133+ cancer stem cells in glioblastoma. Mol Cancer 5:67, 2006
47. Todaro M, Alea MP, DiStefano AB, et al: Colon cancer stem cells dictate tumor growth and resist cell death by production of interleukin-4. Cell Stem Cell 1:389-402, 2007
48. Wulf GG, Wang R-Y, Kuehnle I, et al: A leukemic stem cell with intrinsic drug efflux capacity in acute myeloid leukemia. Blood 98:1166-1173, 2001
49. Hirschmann-Jax C, Foster AE, Wulf GG, et al: A distinct "side population" of cells with high drug efflux capacity in human tumor cells. Proc Natl Acad Sci U S A 101:14228-14233, 2004
50. Wang FP, Wang L, Yang JS, et al: Reversal of P-glycoprotein-dependent resistance to vinblastine by newly synthesized bisbenzylisoquinoline alkaloids in mouse leukemia P388 cells. Biol Pharm Bull 28:1979-1982, 2005
51. Gréen H, Soderkvist P, Rosenberg P, et al: Mdr-1 single nucleotide polymorphisms in ovarian cancer tissue: G2677T/A correlates with response to paclitaxel chemotherapy. Clin Cancer Res 12:854-859, 2006
52. Burger H, vanTol H, Boersma AW, et al: Imatinib mesylate (STI571) is a substrate for the breast cancer resistance protein (BCRP)/ABCG2 drug pump. Blood 104:2940-2942, 2004
53. Sparreboom A, Loos WJ, Burger H, et al: Effect of ABCG2 genotype on the oral bioavailablity of topotecan. Cancer Biol Ther 4:650-658, 2005
54. Chen ZS, Robey RW, Belinsky MG, et al: Transport of methotrexate, methotrexate polyglutamates, and 17beta-estradiol 17 -(beta-D-glucuronide) by ABCG2: Effects of acquired mutations at R482 on methotrexate transport. Cancer Res 63:4048-4054, 2003
55. Magni M, Shammah S, Schiro R, et al: Induction of cyclophosphamide- resistance by aldehydedehydrogenase gene transfer. Blood 87:1097-1103, 1996
56. Pearce DJ, Taussig D, Simpson C, et al: Characterization of cells with a high aldehyde dehydrogenase activity from cord blood and acute myeloid leukemia samples. Stem Cells 23:752-760, 2005
57. Ginestier C, Hur MH, Charafe-Jauffret E, et al: ALDH1 is a marker of normal and malignant human mammary stem cells and a predictor of poor clinical outcome. Cell Stem Cell 1:555-567, 2007
58. Holyoake T, Jiang X, Eaves C, et al: Isolation of a highly quiescent subpopulation of primitive leukemic cells in chronic myeloid leukemia. Blood 94:2056-2064, 1999
59. Guan Y, Hogge DE: Proliferative status of primitive hematopoietic progenitors from patients with acute myelogenous leukemia (AML). Leukemia 14:2135-2141, 2000
60. Folkman J: Angiogenesis: An organizing principle for drug discovery? Nat Rev Drug Discov 6:273-286, 2007
61. Hurwitz H, Fehrenbacher L, Novotny W, et al: Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer. N Engl J Med 350:2335-2342, 2004
62. Vredenburgh JJ, Desjardins A, Herndon JE Jr, et al: Phase II trial of bevacizumab and irinotecan in recurrent malignant glioma. Clin Cancer Res 13: 1253-1259, 2007
63. Jain RK: Normalization of tumor vasculature: An emerging concept in antiangiogenic therapy. Science 307:58-62, 2005
64. Bao S, Wu Q, Sathornsumetee S, et al: Stem cell-like glioma cells promote tumor angiogenesis through vascular endothelial growth factor. Cancer Res 66:7843-7848, 2006
65. Oka N, Soeda A, Inagaki A, et al: VEGF promotes tumorigenesis and angiogenesis of human glioblastoma stem cells. Biochem Biophys Res Commun 360:553-559, 2007
66. Calabrese C, Poppleton H, Kocak M, et al: A perivascular niche for brain tumor stem cells. Cancer Cell 11:69-82, 2007
67. Riquelme PA, Drapeau E, Doetsch F: Brain micro-ecologies: Neural stem cell niches in the adult mammalian brain. Philos Trans R Soc Lond B:1-15, 2007
68. Carmeliet P: Blood vessels and nerves: Common signals, pathways and diseases. Nat Rev Genet 4:710-720, 2003
69. Moeller BJ, Dreher MR, Rabbani ZN, et al: Pleiotropic effects of HIF-1 blockade on tumor radiosensitivity. Cancer Cell 8:99-110, 2005
70. Blazek ER, Foutch JL, Maki G: Daoy medullo-blastoma cells that express CD133 are radioresistant relative to CD133- cells, and the CD133+ sector is enlarged by hypoxia. Int J Radiat Oncol Biol Phys 67:1-5, 2007
71. Lee CG, Heijn M, Tomaso ED, et al: Antivascular endothelial growth factor treatment augments tumor radiation response under normoxic or hypoxic conditions. Cancer Res 60:5565-5570, 2000
72. Hess C, Vuong V, Hegyi I, et al: Effect of VEGF receptor inhibitor PTK787/ZK222584 [correction of ZK222548] combined with ionizing radiation on endothelial cells and tumour growth. Br J Cancer 85:2010-2016, 2001
73. Li J, Huang S, Armstrong EA, et al: Angiogenesis and radiation response modulation after vascular endothelial growth factor receptor-2 (VEGFR2) blockade. Int J Radiat Oncol Biol Phys 62:1477-1485, 2005
74. Yilmaz OH, Valdez R, Theisen BK, et al: Pten dependence distinguishes haematopoietic stem cells from leukaemia-initiating cells. Nature 441:475-482, 2006